"If you're persistent, you can get there. If I think it's gonna be meaningful, I'm willing to do whatever it takes." In this episode of The Biotech Startups Podcast, Amy Hay, Chief Business Officer at CTMC, shares how she transformed ground-level patient care experience at MD Anderson into high-impact leadership that reshaped cancer treatment delivery. She traces her path from MD Anderson's first-ever internal administrative fellow to spearheading the institution's first proton therapy center and pioneering satellite clinics—including a "flea-bitten" Bellaire, Texas facility that became a runaway success by prioritizing convenience, compassion, and continuity of care. Amy recounts the audacious multi-year journey of raising 125 million dollars by assembling an unlikely coalition of clinicians, physicists, investment bankers, and construction operators, weathering the shock of 9/11 and frozen capital markets, then pivoting to purpose-driven local investors like firefighters' and police officers' pension funds whose communities are directly impacted by cancer. Along the way, Amy reflects on the challenges of intrapreneurship inside a major academic medical center, the unexpected emotional letdown that follows a "big win," and how that restlessness ultimately pushed her toward global oncology. She shares how collaborations with Hospital Albert Einstein in São Paulo, the American Hospital in Istanbul, and other international partners expanded her perspective beyond elite U.S. centers, sharpening her focus on access, alignment, and building care models that work across diverse health systems—not just in Houston.